PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently ...
PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
Zacks Investment Research on MSN
10x Genomics, Cleveland Clinic team up on bladder cancer diagnostics
10x Genomics TXG recently entered into a multi-year research collaboration with the Cleveland Clinic to advance novel diagnostic applications for bladder cancer. The study will use the company's Flex ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x ...
Citi analyst Patrick B Donnelly has maintained their bullish stance on TXG stock, giving a Buy rating today. Patrick B Donnelly has given his Buy rating due to a combination of factors. In 3Q23, 10x ...
PLEASANTON, Calif. - 10x Genomics, Inc. (NASDAQ:TXG), a life sciences technology company with a market capitalization of $1.7 billion and impressive gross margins of nearly 70%, announced Tuesday the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results